IOMED, member of CataloniaBio & HealthTech and a leader in Artificial Intelligence for health data activation, has recently announced the closing of a €10 million Series A investment round.  

Asabys Partners, member of CataloniaBio & HealthTech, has led a Series A financing round of 14 million euros and Gradient Denervation Technologies has announced the closing of this round. The aim of this round is to support the clinical development and evaluation of the ultrasound-based ablation catheter through the new Sabadell Asabys II fund. 

Integra Therapeutics, member of CataloniaBio & HealthTech, will present positive fata from ex vivo and in vivo preclinical studies that demonstrates the potential of its FiCAT gene-writing platform for developing advanced therapies in the field of paediatric hepatology at the Advanced therapies Europe congress. 

Anaxomics, member of CataloniaBio & HealtTech, announced the appointment of Peter M. Windisch as its Chief Executive Officer (CEO), effective September 1st, 2023. 

More than thirty CEOs of CataloniaBio & HealthTech met at the HUB cambraDigital (Barcelona Chamber of Commerce) on 22 June for the last CEO Council before the summer break. The special guest at this edition was Núria Mas, currently a professor of economics at the IESE Business School. 

Asabys Partners, Barcelona-based VC firm focused on healthcare innovation investing from its fund Sabadell Asabys II, joins AdBio Partners, French life sciences venture capital firm and initial investor, both CataloniaBio & HealthTech members.

Trifermed, member of CataloniaBio & HealthTech, is proud to announces the upcoming 7th edition of the trifermed awards for social impact in healthcare. Aim to recognize individuals and organizations that are dedicated to improving the quality of health and making a positive impact on society. By honoring those who wake up every morning driven by passion and a desire to develop a better world, these awards highlight the importance of social responsibility and ethical practices in healthcare. 

The Biostatistics Unit has recently joined the technologies and services offered by the Germans Trias i Pujol Research Institute (IGTP), partners of CataloniaBio & HealthTech. 

Inteplast, member of CataloniaBio & HealthTech, was founded in 1972 and is celebrating its 50th anniversary as a leading company in the design, development and manufacture of high-performance thermoplastic solutions, with its sights set on the future in Industry 4.0, innovation, technology, quality and sustainability. 

The company Affirma Biotech has opened a round of funding on the Capital Cell platform, both members of CataloniaBio & HealthTech. The biotech company hopes to raise 600,000 euros to confirm the efficacy of its new compounds as immune system activators for the treatment of severe viral and bacterial infections of the broad spectrum.

Les empreses REIG JOFRE (BME:RFJ), companyia farmacèutica cotitzada al mercat continu de la borsa espanyola i membre de CataloniaBio &HealthTech, i la biotecnològica CZ VACCINES, (del grup Zendal) han signat un acord amb l’Agència Executiva Europea en els àmbits de Salut i Digital (HaDEA, per les seves sigles enanglès) per reservar capacitat de producció de vacunes.

Exheus, the company located at the TecnoCampus and a member of CataloniaBio & HealthTech, specialised in the analysis of gene expression using artificial intelligence (AI), has announced the launch of Beyond You. This new brand is accompanied by a digital platform that will provide healthcare professionals with personalised information to optimise the diagnosis and treatment of their patients.

BHV Partners has opened a seed funding round of €2.5 million to accelerate its growth as a venture builder specialising in creating start-ups in thehealth sector. The round is aimed at family offices and companies with corporate venture funds, as well as existing partners.

Creatio, partner of CataloniaBio & Health Tech and production and validation centre for advanced therapies of the University of Barcelona, through the Bosch i Gimpera Foundation, has acquired UTOX, the experimental toxicology platform of the Barcelona Science Park (PCB). The aim of this acquisition is for UTOX to be integrated into the Creatio technology development centre, a leader in advanced therapies and a member of the TECNIO network. 

OneChain Immunotherapeutics, spin-off from the Josep Carreras Leukaemia Research Institute and Dr. Pablo Menéndez, as well as a portfolio company of OneChain, both partners of CataloniaBio & HealthTech, announce the closing of a pre-series financing round where they have counted with the participation of Invivo Capital, also partners. 

Ysios Capital, a leading venture capital firm in the biotech sector and member of CataloniaBio & HealthTech, announced today its participation in the financing round of the Dutch company Tagworks Pharmaceuticals for a total amount of 64 million dollars (over 58 million euros).

A total of 51 companies in 17 countries have been selected by the European Innovation Council Accelerator, in a competitive process involving 551 candidates. MiMARK Diagnostics and the Madrid-based company, Oils4Cure have been the only Spanish companies to be chosen.

GENESIS Tech Transfer Boost, an investment vehicle created in 2022 and managed by the consultancy firm GENESIS Biomed, has made its first investment for a ticket of €25,000 in the biotech company Spinally Medical. The vehicle formed by GENESIS Biomed, FI Group and Crowd4Ventures for a total of €1M for 4 years, aims to detect and invest in early-stage projects in the biomedical sector from the health and academic environments.

Biotech company SpliceBio, members of CataloniaBio & HealthTech, has announced the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer (CDO). Dr. Favre brings extensive experience in gene therapy, immunology and drug development. 

Nuage Therapeutics (“Nuage”), companyia biotecnològica que desenvolupa un motor de descobriment de nous fàrmacs moduladors de proteïnes intrínsecament desordenades (IDPs), anuncia avui el tancament d’un finançament inicial de 12 milions d’euros per donar suport al desenvolupament del seu programa principal i validar la seva plataforma pionera de descobriment de fàrmacs